Genetic susceptibility to lead poisoning

Environmental Health Perspectives

Volumn 108, Issue SUPPL. 1, 2000, Pages 23-28

  Onalaja, Ava O ^a   Claudio, Luz ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

ALAD; Hereditary hemochromatosis; Lead accumulation; Lead toxicity; Polymorphism; Vitamin D receptor; aminolevulinic acid dehydratase

Indexed keywords

CALCIUM; DNA; HEME; IRON; ISOENZYME; LEAD; PORPHOBILINOGEN SYNTHASE; VITAMIN D RECEPTOR;

BIOACCUMULATION; BONE; CALCIUM ABSORPTION; DNA POLYMORPHISM; GENETIC MARKER; GENETIC SUSCEPTIBILITY; HEME SYNTHESIS; HEMOCHROMATOSIS; HOMOZYGOTE; HUMAN; INTESTINE ABSORPTION; IRON TRANSPORT; LEAD POISONING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR GENE; REVIEW;

EID: 0034075931     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.00108s123     Document Type: Review

References (94)

1. Todd AC, Wetmur JG, Moline JM, Godbold JH, Levin SM, Landrigan PJ Unraveling the chronic toxicity of lead: an essential priority for environmental health. Environ Health Perspect 104 (suppl 1): 141-146 (1996).
2. Mushak P. Defining lead as the premiere environmental health issue for children in America: criteria and their quantitative application. Environ Res 59:281-309 (1992).
3. Schaffer SJ, Campbell JR. The new CDC and AAP lead poisoning prevention recommendations: consensus versus controversy Pediatr Ann 23:592-599 (1994).
4. National Academy of Sciences (NAS) Lead: Airborne Lead in Perspective: Biologic Effects of Atmospheric Pollutants. Washington, DC National Academy of Sciences, 1972.
5. Florini KL, Krumbhaar GD, Silbergeld EK. Legacy of Lead: America's Continuing Epidemic of Childhood Lead Poisoning. A Report and Proposal for Legislative Action. Washington, DC Environmental Defense Fund, 1990.
6. Rudner N. Children with elevated lead levels. J Pediatr Health Care 2:46-49 (1988).
7. Goyer RA. Lead toxicity from overt to subclinical to subtle health effects. Environ Health Perspect 86:177-181 (1990).
8. Goyer RA. Mechanisms of lead and cadmium nephrotoxicity. Toxicol Lett 46:153-162 (1989).
9. Chia KS, Jeyaratnam J, Lee J, Tan C, Ong HY, Ong CN, Lee E. Lead-induced nephropathy: relationship between various biological exposure indices and early markers of nephrotoxicity. Am J Ind Med 27:883-895 (1995).
10. Wright RO. The role of iron therapy in childhood plumbism. Curr Opin Pediatr 11:255-258 (1999).
11. Lancranan l, Popescu HI, Gavanescu O, Klepsch I, Serbanescu M. Reproductive ability of workmen occupationally exposed to lead. Arch Environ Health 30:396-401 (1975).
12. Hu H. Knowledge of diagnosis and reproductive history among survivors of childhood plumbism. Am J Public Heath 81:1070-1072 (1991).
13. Prikle JL, Schwartz J, Landis R, Harlan WR. The relationship between blood lead levels and its cardiovascular risk implications. Am J Epidemol 121:246-258 (1985).
14. de Corte W, Vershoor MA, van Hemmen JJ. Occupational exposure to lead and blood pressure: a study of 105 workers. Am J Ind Med 11:145-156 (1987).
15. Neddleman HL, Schell A, Bellinger D, Leviton A, Allred EN. The long-term effects of exposure to low levels of lead in childhood. An 11 year follow-up report. N Engl J Med 322:83-88 (1991).
16. Needleman HL, Gunnoe C, Leviton A, Deficits in psychologic and classroom performance in children with elevated dentine lead levels. N Engl J Med 300:689-659 (1979).
17. Needleman HL, Gatsonis CA. Low lead exposure and the IQ of children: a meta analysis of modern studies. J Am Med Assoc 263:673-678 (1990).
18. Needleman HL, Bellinger D. The health effects of low level exposure to lead. Annu Rev Public Health 38:83-88 (1991).
19. Bellinger D, Leviton A, Waternaux C, Needleman H, Rabinowitz M. Longitudinal analyses of prenatal and postnatal lead exposure and early cognitive development. N Engl J Med 316: 1037-1043 (1987).
20. ATSDR. Toxicological Profile for Lead. TP-92/12. Atlanta, GA:Agency for Toxic Substances and Disease Registry, 1993.
21. U.S. EPA. Air Quality Criteria for Lead. EPA 600/8-83-028F. Washington, DC:U.S. Environmental Protection Agency, 1986.
22. Billick IH. Lead: a case study in interagency policy-making. Environ Health Perspect 42:73-79 (1981).
23. Claudio I, Lee T, Wolf MS, Wetmur JG. A murine model of genetic susceptibility to lead bioaccumulation. Fundam Appl Toxicol 35:84-90 (1997).
24. 2) allele: implications for molecular screening of individuals for genetic susceptibility to lead. Am J Hum Genetic 49(4):757-763 (1991).
25. Kaiser J. Environment Institute lays plans for gene hunt. Science 274:569-570 (1997).
26. Devlin TM. Textbook of Biochemistry. Fourth ed. New York:Wiley-Liss, 1997;906-907.
27. Bergdahl IA, Grubb A, Schutz A, Desnick RJ, Wetmur JG, Sassa S, Skerfving S. Lead binding to δ-aminolevulinic acid dehydratase (ALAD) in human erythrocytes. Pharmacol Toxicol 81:153-158 (1997).
28. Secchi GC, Erba L, Cambiaghi G. δ-Aminolevulinic acid dehydratase activity of erythrocytes and liver tissue in man. Arch Environ Health 28:130-132 (1974).
29. Klaassen CD. Casarett and Doull's Toxicology: The Basic Science of Poisons. Fifth ed. New York:Pergamon Press, 1996;705-709.
30. Sakai T, Morita Y. δ-Aminolevulinic acid in plasma or whole blood as a sensitive indicator of lead effects, and its relation to the other heme-related parameters. Int Arch Occup Environ Health 68:126-132 (1996).
31. Tomokuni K, Ichiba M, Hirai Y. Elevated urinary excretion of b-aminoisobutyric acid and δ-aminolevulinic acid (ALA) and the inhi-bition of ALA-synthase and ALA-dehydratase activities in both liver and kidney in mice exposed to lead. Toxicol Lett 59:169-173 (1991).
32. Goering PL. Lead-protein interactions as a basis for lead toxicity. Neurotoxicology 14:45-60 (1993).
33. Astrin KH, Bishop DF, Wetmur JG, Kaul BC, Davidow B, Desnick RJ. Aminolevulinic acid dehydratase isozymes and lead toxicity. Ann NY Acad Sci 514:23-29 (1987).
34. Sithisarankul P, Schwartz BS, Lee BK, Strickland PT. Urinary 5-aminolevulinic acid (ALA) adjusted by creatinine: a surrogate for plasma ALA? J Occup Environ Med 40(10):901-906 (1998).
35. Sassa S. ALAD porphyria. Semin Liver Dis 18(1):95-101 (1998).
36. Sithisarankul P, Schwartz BS, Lee BK, Kelsey KT, Strickland PT. Aminolevulinic acid dehydratase genotype mediates plasma levels of the neurotoxin, 5-aminolevulinic acid, in lead-exposed workers. Am J Ind Med 32:15-20 (1997).
37. Blumberg WE, Eisinger J, Lamola AA, Zuckerman DM. Principles and applications of hematofluorometry. J Clin Lab Automation 4:29-42 (1984).
38. Petrucci R, Leonardi A, Battistuzzi G. The genetic polymorphism of δ-aminolevulinate dehydratase in Italy. Hum Genet 60: 289-290 (1982).
39. Wetmur JG, Bishop DF, Cartelmo C, Desnick RJ Human δ-aminolevulinate dehydratase: nucleotide sequence of a full-length cDNA clone. Proc Natl Acad Sci USA 83:7703-7707 (1986).
40. Potluri VR, Astrin KH, Wetmur JG, Bishop DF, Desnick RJ. Human δ-aminolevulinate dehydratase: chromosomal localization to 9q34 by in situ hybridization. Hum Genet 76:236-239 (1987).
41. Benkman HG, Gogdaanski P, Goedde HW. Polymorphism of δ-aminolevulinic acid dehydratase in various populations. Hum Hered 33:62-64 (1983).
42. Ziemsen B, Angerer J, Lehnert G, Benkman HG, Goedde HW. Polymorphism of δ-aminolevulinic acid dehydratase in lead exposed workers. Int Arch Occup Environ Health 58:245-247 (1986).
43. Wetmur JG, Lehnett G, Desnick RJ. The δ-aminolevulinate dehydratase polymorphism: higher blood lead levels in lead workers and environmentally exposed children with 1-2 and 2-2 isozymes. Environ Res 56:109-119 (1991).
44. Smith CM, Wang X, Howard H, Kelsey KT. A polymorphism in the δ-aminolevulinic acid dehydratase gene may modify the pharmacokinetics and toxicity of lead. Environ Health Perspect 103:248-253 (1995).
45. Schwartz BS, Lee BK, Stewart W, Ahn KD, Springer K, Kelsey K. Associations of delta-aminolevulinic acid dehydratase genotype with plant, exposure duration, and blood lead and zinc protoporphyrin levels in Korean lead workers. Am J Epidemiol 142:738-745 (1995).
46. Schwartz BS, Lee BK, Stewart W, Ahn KD, Kelsey K, Bressler J. Associations of subtypes of hemoglobin with δ-aminolevulinic acid dehydratase genotype and dimercaptosuccinic acid-chelatable lead levels. Arch Environ Health 52:97-103 (1997).
47. Bergdahl IA, Sheveleva M, Schutz A, Artamonova VG, Skerfving S. Plasma and blood lead in humans: capacity-limited binding to δ-aminolevulinic acid dehydratase and other lead-binding components. Toxicol Sci 46:247-253 (1998).
48. Schwartz BS, Lee BK, Stewart W, Sithisarankul P, Strickland PT, Ahn KD, Kelsey K. δ-Aminolevulinic acid dehydratase gentoype modifies four hour urinary lead excretion after oral administration of dimercaptosuccinic acid. Occup Environ Med 54:241-246 (1997).
49. Bergdahl IA, Gerhardsson L, Schutz A, Desnick RJ, Wetmur JG, Skerfving S. δ-Aminolevulinic acid dehydratase polymorphism: influence on lead levels and kidney function in humans. Arch Environ Health 52:91-96 (1997).
50. Silbergeld EK, Lamon JM. Effects of altered porphyrin synthesis on brain neurochemistry. Neurobehav Toxicol Teratol 4:635-642 (1982).
51. Bellinger D, Hu H, Titlebaum I, Needleman HL. Attentional correlates of dentin and bone lead levels in adolescents. Arch Environ Health 49:98-105 (1994).
52. 2+ on neuronal nicotinic acetylcholine receptors. Neurotoxicology 18:709-717 (1997).
53. Fleming DE, Chettle DR, Wetmur JG, Desnick RJ, Robin JP, Boulay D, Richard NS, Gordon CL, Webber CE. Effect of the δ-aminolevulinate dehydratase polymorphism on the accumulation of lead in bone and blood in lead smelter workers. Environ Res 77:49-61 (1998).
54. Alexander BH, Checkoway H, Costa-Mallen P, Faustman EM, Wookds JS, Kelsey KT, van Netten C, Costa LG. Interaction of blood lead and delta-aminolevulinic acid dehycreatase genotype on markers of heme synthesis and sperm production in lead smelter workers. Environ Health Perspect 106: 213-216 (1998).
55. Doyle D, Schimke RT. The genetic and developmental regulation of hepatic delta-aminolevulinate dehydratase in mice. J Biol Chem 244:5449-5459 (1969).
56. Hutton JJ, Coleman DL. Linkage analyses using biochemical variants in mice. II. Levulinate dehydratase and autosomal glucose 6-phosphate dehydrogenase. Biochem Genet 3:517-523(1969).
57. Bishop TR, Cohen PJ, Boyer SH, Noyes AN, Frelin LP. Isolation of a rat liver δ-aminolevulinate dehydratase (ALAD) cDNA clone. Evidence for unequal ALAD gene dosage among inbred mouse strains. Proc Natl Acad Sci USA 83:5568-5572 (1986).
58. Wetmur JG. Influence of the common human delta-aminolevulinate dehydratase polymorphism on lead body burden. Environ Health Perspect 102(suppl 3):215-219 (1994).
59. Wasserman RH, Fullmer CS. Vitamin D and intestinal calcium transport facts, speculations and hypotheses. J Nutr 125:1971S-1979S(1995).
60. Pounds JG. Effect of lead intoxication on calcium homeostasis and calcium-mediated cell function: a review. Neurotoxicology 5:295-331 (1984).
61. Six KM, Goyer RA. Experimental enhancement of lead toxicity by low dietary calcium. J Lab Clin Med 76:933-942 (1970).
62. Mykkanen HM, Wasserman RH. Gastrointestinal absorption of lead (203Pb) in chicks: Influence of lead, calcium and age. J Nutr 111:1757-1765(1981).
63. Fullmer CS. Intestinal interactions of lead and calcium. Neurotoxicology 13:799-807 (1992).
64. Fullmer CS, Edelstein S, Wasserman RH. Lead-binding properties of intestinal calcium-binding proteins. J Biol Chem 260:6816-6819(1985).
65. Fullmer CS. Intestinal calcium and lead absorption: Effects of dietary lead and calcium. Environ Res 54:159-169 (1991).
66. 2+-binding proteins. Biochem Pharmacol 35:1331-1335(1986).
67. Moon J. The role of vitamin D in toxic metal absorption: a review. J Am Coll Nutr 13:559-564 (1994).
68. Fullmer CS. Lead-calcium interactions: involvement of 1,25-dihydroxyvitamin D1. Environ Res 72:45-55 (1997).
69. Morrison NA, Yeoman R, Kelly PJ, Eisman JA. Contribution of trans-acting factor alleles to normal physiological variability: vitamin D receptor gene polymorphism and circulating osteocalcin. Proc Natl Acad Sci USA 89:6665-6669 (1992).
70. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eisman JA. Prediction of bone density from vitamin D receptor alleles. Nature 367:284-287 (1994).
71. Gong G, Stern HS, Cheng SC, Fong N, Mordenson J, Deng HW, Recker RR. The association of bone mineral density with vitamin D receptor gene polymorphisms. Osteoporos Int 9:55-64 (1999).
72. Tao C, Yu T, Gamett S, Briody J, Knight J, Woodhead H, Cowell CT. Vitamin D receptor alleles predict growth and bone density in girls. Arch Dis Child 79:488-493 (1998).
73. Gough A, Sambrook P, Devlin J, Huisoon A, Betteridge J, Franklyn J, Nguyen T, Morrison N, Eisman J, Emery P. Effect of vitamin D receptor gene alleles on bone loss in early rheumatoid arthritis. J Pheumatol 25:864-868 (1998).
74. Ames SK, Ellis KJ, Gunn SK, Copeland KC, Abrams SA. Vitamin D receptor gene Fok1 polymorphism predicts calcium absorption and bone mineral density in children. J Bone Miner Res 14:740-746(1999).
75. Tokita A, Matsumoto H, Morrison NA, Tawa T, Miura Y, Fukamauchi K, Mitsuhashi N, Irimoto M, Yamamori S, Miura M, et al. Vitamin D receptor alleles, bone mineral density and turnover in premenopausal Japanese women. J Bone Miner Res 11:1003-1009 (1996).
76. Ferrari S, Manen D, Bonjour JP, Slosman D, Rizzoli R. Bone mineral mass and calcium and phosphate metabolism in young men: relationships with vitamin D receptor allelic polymorphisms. J Clin Endocrinol Metab 84: 2043-2048 (1999).
77. White CP, Morrison NA, Gardiner EM, Eisman JA. Vitamin D receptor alleles and bone physiology. J Cell Biochem 56:307-314 (1994).
78. Howard G, Nguyen T, Morrison N, Watanabe T, Sambrook P, Eisman J, Kelly PJ. Genetic influences on bone density: physiological correlates of vitamin D receptor gene alleles in premenopausal women. J Clin Endocrinol Metab 80:2800-2805 (1995).
79. Cooper GS, Umback DM. Are vitamin D receptor polymorphisms associated with bone mineral density? A meta-analysis. J Bone Miner Res 11:1841-1849(1996).
80. Need AG, Horowitz M, Stiliano A, Scopacasa F, Morris HA, Chatterton BE. Vitamin D receptor genotypes are related to bone size and bone density in men. Eur J Clin Invest 26: 793-796 (1996).
81. Kosnet MJ, Becker CE, Osterloh JD, Kelly TJ, Pasta DJ. Factors influencing bone lead concentration in a suburban community assessed by noninvasive K X-ray fluorescence. J Am Med ASSDC 271:197-203(1994).
82. Hu H, Payton M, Korrick S, Aro A, Sparrow D, Weiss ST, Rotnitzky A. Determinants of bone and blood lead levels among community-exposed middle-aged to elderly men. Am J Epidemiol 144:749-759(1996).
83. Schwartz BS, Stewart WF, Kelsey K, Simon D, Park S, Links JM, Todd AC. Associations of tibial lead levels with Bsml polymorphisms in the vitamin D receptor in former organolead manufacturing workers. Environ Health Perspect (in press).
84. Jazwinska EC. Hemochromatosis: a genetic defect in iron metabolism. Biosassays 20:562-568 (1998).
85. Burt MJ, George PM, Upton JD, Collett JA, Frampton CM, Chapman TM, Walmsley TA, Chapman BA. The significance of haemochromatosis gene mutations in the general population: implications for screening. Gut 43:830-836 (1998).
86. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R Jr, Ellis MC, Fullan A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13:399-408 (1996).
87. Gross CN, Irrinki A, Feder JN, Enns CA. Co-trafficking of HFE, a nonclassical major histocompatibility complex class I protein, with the transferrin receptor implies a role in intracellular iron regulation. J Biol Chem 273:22068-22074 (1998).
88. Wright RO, Shannon MW, Wright RJ, Hu H. Association between iron deficiency and low-level lead poisoning in an urban primary care clinic. Am J Public Health 89:1049-1053 (1999).
89. Ruff HA, Markowitz ME, Bijur PE, rosen JF. Relationships among blood lead levels, iron deficiency, and cognitive development in two-year old children. Environ Health Perspect 104:180-185 (1996).
90. Barton JC, Patton MA, Edwards CQ, Griffen LM, Kushner JP, Meeks RG, Leggett RW. Blood lead concentrations in hereditary hemochromatosis. J Lab Clin Med 124:193-198 (1994).
91. Roy CN, Penny DM, Feder JN, Enns CA. The hereditary hemochromatosis protein, HFE, specifically regulates transferrin-mediated iron uptake in HeLa cells. J Biol Chem 274:9022-9028 (1999).
92. Basclain KA, Shilkin KB, Withers G, Reed WD, Jeffrey GP. Cellular expresssion and regulation of iron transport and storage proteins in genetic haemochromatosis. J Gastroenterol Hepatol 13:624-634(1998).
93. Fleming RE, Migas MC, Zhou X, Jiang J, Britton RS, Brunt EM, Tomatsu S, Waheed A, Bacon BR, Sly WS. Mechanism of increased iron absroption in murine model of hereditary hemocromatosis: increased duodenal expression of the iron transporter DMT1. Proc Natl Acad Sci USA 96:3134-3148 (1999).
94. Zoller H, Pietrangelo A, Vogel W, Weiss G. Duodenal metal-transporter (DMT-1, NRAMP-2) expression in patients with hereditary haemochromatosis. Lancet 353:2120-2123 (1999).